| About the author: |
O. O. Abrahamovych, M. O. Abrahamovych, M. L. Farmaha, Y. L. Leshchuk, L. V. Tsyhanyk, T. I. Farmaha, Y. S. Leshchuk |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
Liver cirrhosis is a common disease occurring mainly among people of working age and frequently resulting in lethal outcomes. The causes of such epidemiology of liver cirrhosis are syntropic comorbid lesions, in particular lesions of the circulatory system organs. The study was carried out in three consecutive steps, namely: in the first phase the proportion of patients with liver cirrhosis with extrahepatic cardiovascular lesions was revealed, in the second, the frequency of each individual cardiovascular disease in patients was evaluated, and in the third phase the frequency of cardiovascular system lesions in every severity class of liver cirrhosis in accordance with C.G. Child-R.N. Pugh criteria and correlation between their incidence and class of cirrhosis were revealed. 81.3 % of patients with liver cirrhosis have lesions of the circulatory system, among which cirrhotic cardiomyopathy and disorders in the system of blood pressure regulation with the emergence of persistent arterial hypotension have common pathogenetic mechanisms with liver cirrhosis, namely, they are syntropic, whilst postinfarction cardiosclerosis, angina pectoris, acquired heart defects, and painless form of coronary heart disease are concomitant. |
| Tags |
liver cirrhosis,cardiomyopathy,arterial hypertension,syntropic lesions |
| Bibliography |
- Abrahamovych MO, Farmaha ML. Klinichni markery syntropichnykh komorbidnykh urazhen systemy krovoobihu u khvorykh na tsyroz pechinky. Lvivskyi klinichnyi visnyk. 2018;1(21), 2(22):30–40. DOI:https://doi.org/10.25040/lkv2018.01.030 [in Ukrainian]
- Kolesnikova EV. Sovremennyy patsiyent s zabolevaniyem pecheni i patologiyey serdechno-sosudistoy sistemy: kakoy vybor sdelat? Suchasna hastroenterolohiia. 2014; 2(76):85–94 [in Russian]
- Bolognesi M, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol. 2014; 20(10):2555–2563. Doi: 10.3748/wjg.v20.i10.2555
- Carvalho MVH, Kroll PC, Kroll RTM, Carvalho VN. Cirrhotic Cardiomyopathy: The Liver Affects the Heart. Braz J Med Biol Res. 2019; 52 (2):e7809. Doi: 10.1590/1414-431X20187809
- Cesari M, Frigo AC, Tonon M, Angeli P. Cardiovascular predictors of death in patients with cirrhosis. Hepatology. 2018 Jul; 68(1):215–223. Doi: 10.1002/hep.29520
- Kim HM, Kim HK, Lee JH, Lee YB, Park EA, Park JB, et al. Myocardial structural and functional changes in patients with liver cirrhosis awaiting liver transplantation: a comprehensive cardiovascular magnetic resonance and echocardiographic study. J Cardiovasc Magn Reson. 2020 Apr 23;22(1):25. Doi: 10.1186/s12968-020-00622-2
- Liu H, Jayakumar S, Traboulsi M, Lee SS. Cirrhotic Cardiomyopathy: Implications for Liver Transplantation. Liver Transpl. 2017; 23(6):826–835. Doi: 10.1002/lt.24768
- Moller S, Danielsen KV, Wiese S, Hove JD, Bendtsen F. An update on cirrhotic cardiomyopathy. Expert Rev Gastroenterol Hepatol. 2019 May; 13(5):497–505. Doi: 10.1080/17474124.2019.1587293
- Stundiene I, Sarnelyte J, Norkute A, Aidietiene S, Liakina V, Masalaite L, et al. Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review. World J Gastroenterol. 2019; 25(32):4779–4795. Doi: 10.3748/wjg.v25.i32.4779
- Yao H, Zhang C. Angiotensin II Receptor Blockers for the Treatment of Portal Hypertension in Patients With Liver Cirrhosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ir J Med Sci. 2018; 187(4):925–934. Doi: 10.1007/s11845-018-1765-6
|
| Publication of the article |
«World of Medicine and Biology» №1(79), 2022 year, 007-011 pages, index UDK 616.36-004-036-06:616.12-008.1]-079.4 |
| DOI |
10.26724/2079-8334-2022-1-79-7-11 |
